Abstract
Chronic respiratory disorders affect millions of people worldwide. Pathophysiological changes to the normal airway wall structure, including changes in the composition and organization of its cellular and molecular constituents, are referred to as airway remodeling. The inadequacy of effective treatment strategies and scarcity of novel therapies available for the treatment and management of chronic respiratory diseases have given rise to a serious impediment in the clinical management of such diseases. The progress made in advanced drug delivery, has offered additional advantages to fight against the emerging complications of airway remodeling. This review aims to address the gaps in current knowledge about airway remodeling, the relationships between remodeling, inflammation, clinical phenotypes and the significance of using novel drug delivery methods.
Original language | English |
---|---|
Pages (from-to) | 271-288 |
Number of pages | 18 |
Journal | Future Medicinal Chemistry |
Volume | 14 |
Issue number | 4 |
DOIs | |
Publication status | Published (in print/issue) - 12 Jan 2022 |
Bibliographical note
Funding Information:PM Hansbro is funded by a fellowship and grants from the National Health and Medical Research Council (NHMRC) of Australia (1175134) and by UTS. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.
Publisher Copyright:
© 2022 Saurabh Satija.
Keywords
- inflammation
- therapeutic interventions
- respiratory diseases
- COPD
- NDDS
- remodeling
- respiratory disorders
- Review
- Humans
- Administration, Inhalation
- Inflammation/metabolism
- Lung/anatomy & histology
- Pulmonary Disease, Chronic Obstructive/therapy
- Airway Remodeling
- Drug Carriers/chemistry
- Medication Adherence
- Asthma/therapy